Xiuning Le MD PhD
@LeXiuning
Followers
2K
Following
3K
Media
127
Statuses
279
Associate Professor Thoracic Head and Neck Medical Oncology MD Anderson Cancer Center
Houston, TX
Joined March 2020
Honored to present at @sitcancer for HARMONi-A trial final OS. ๐Echo @HTawbi_MD that we are marking evolution of PD-1 blockade. @MDAndersonNews @lungoncdoc @oncodaily @OncoViews
Dr. โฆ@LeXiuningโฉ presenting โฆ@sitcancerโฉ FINAL OS results from ivonescimab + carbo/pem in TKI-refractory EGFR-NSCLC, HR 0.74, p=0.019. Benefit strongest in pts with brain mets HR 0.61, regimen approved in China. Impressive results marking evolution of PD-1 blockade
3
16
55
Honored to share my ๐ SECOND simultaneous publication at #ESMO25 ๐, published in ๐ @AnnalsOfOncology ๐ Our global leptomeningeal disease (#LMD) from #NSCLC cohort study (2,052 patients) sets benchmark outcomes for this rare population and generates hypotheses for
Thrilled to share our global, multicenter study on leptomeningeal disease in NSCLC. None of this is possible without the dedication of participating centers and shared commitment for the vulnerable pts! @ThomasW35874311 @LeXiuning @KelseyPanMD @danieltanmd @HwakeleeMD @Alfdoc2
1
21
90
I also want to thank the incredible teams at @MDAndersonNews, @broadinstitute , and @Bayer, we push the boundaries of precision oncology for patients. We delivered high quality work ๐ช ๐ช ๐ช yet remain fun ๐ and humble โฅ๏ธ @NEJM @myESMO #ESMO25
๐ฅBREAKINGโผ๏ธ @NEJM ๐ โ
Sevabertinib in Advanced HER2-Mutant NonโSmall-Cell Lung Cancer ๐ฏmPFS (PreTx w/o HER2, Pre HER2-ADC, Tx-naive): 8.3m, 5.5m, and not reached ๐๏ธ @LeXiuning
#ESMO25 #LCMS @myESMO @OncoAlert @Larvol
https://t.co/gV2x6sGsoN
7
19
118
What is on your calendar? #LungCancer #Berline #ESMO25 ๐
Friday, Oct 17 Proffered: Metastatic NSCLC ๐Xiuning Le ๐โ SOHO-01: Sevabertinib in HER2+ NSCLC @MDAndersonNews @lungoncdoc ๐Sanjay Popat โ Beamion-Lung-01: Zongertinib in HER2+ NSCLC 1L @DrSanjayPopat ๐Yasir Elamin
2
14
42
Are we ready for ultra-precision oncology? ๐ฌโจ ๐ New online: https://t.co/TjzjfTFnMG Differential impact of #EGFR #exon20 insertion location (near- vs. far-loop) on TKI sensitivity ๐ EGFRex20ins can be separated into two distinct groups: near-loop (A767-P772) and far-loop
4
34
92
So proud! ๐ @YYElamin and I will be the first two presenter to open the proffered session for metastatic #NSCLC at #ESMO25. Such an honor to kick off the Congress at the Berlin Auditorium @MDAndersonNews! ๐โจ
7
8
76
๐New online: JCO Sunvozertinib becomes the 1st TKI approved (๐FDA, 2025๐) for EGFR ex20ins NSCLC. ๐ ORR: 45โ47% โฑDoR: 11โ13.8 mo ๐Similar efficacy in near- vs. far-loop insertions ๐งฉORR 25% in pre-treated with Amivantamab Sunvozertinib in Platinum-Pretreated NSCLC
ascopubs.org
PURPOSEWU-KONG1B (ClinicalTrials.gov identifier: NCT03974022) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced...
2
12
69
#WCLC25 @IASLC This is our family, this is our celebration. Great to see everyone in the field of thoracic oncology and exchange ideas. ๐ to @TonyMok9 waring "seeking a mentor" ribbon, we all need to be humble tackling the daunting #lungcancer together. โค๏ธ๐โค๏ธ@DRCamidge
2
9
71
Dr. Camidge @DRCamidge is my mentor, my icon, and my hero. Stephen is right, we must all work together to move the field. To you Ross, best wishes with many๐๐๐โฅ๏ธ @lungoncdoc @OncoViews @OncLive @oncodaily
One of the biggest influences on my career is Dr. Ross Camidge - a mentor and friend, an intellectual giant in the field of lung cancer who was diagnosed with this unforgiving disease himself. We are all at risk - and must all work to move the field. https://t.co/GHuaFBUoBm
0
10
40
Are we ready for ultra-precision oncology? ๐ฌโจ ๐ New online: First-line MET tyrosine kinase inhibitors versus immunotherapy ยฑ chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC https://t.co/weBKYlsyb1 (with @pecci_federica1 @BRicciutiMD @Alfdoc2
1
29
91
Ready to battle: ๐ฆMARIPOSA vs. ๐ธFLAURA2 in 1L #EGFR #lungcancer I will debate, facing off against the brilliant Dr. Tom Newsom-Davis of Westminster ๐บ๐ธโ๏ธ๐ฌ๐ง at #ILCS26 with @Alfdoc2 @peters_solange Your British accent may charm the audience, my friend, but data wins the
At the ILCS on 26แตสฐ September, world-class experts @LeXiuning and @tnewsomdavis will debate evolving standards in EGFR+ metastatic NSCLC. Dr. Le will spotlight the impact of amivantamab + lazertinib, offering a forward-looking view on how this combo is reshaping patient care โฌ๏ธ
5
11
66
๐๐๐We celebrate #FDA approval of #zongertinib as the first TKI in #HER2-mutant #NSCLC ๐ ๐ ๐บ ๐ฉท ๐ ORR 71% ๐ Duration of Response 14.1 months ๐ PFS 12.4 months ๐ Well-tolerated at 120mg dose ๐ In previously treated patients without prior anti-HER2 targeted therapies
3
18
105
First HER2 TKI approval in lung cancer! ๐๐๐ @lungoncdoc @MDAndersonNews @OncoViews
https://t.co/mL6v0FEL87 via @onclive
onclive.com
The FDA granted accelerated approval to zongertinib for pretreated, unresectable or metastatic nonโsmall cell lung cancer harboring HER2 mutations.
2
8
46
Another funny slide from the same presentation ๐คฃ๐คฃ๐คฃ๐คฃ@BalazsHalmosMD #BTGLung2025 @NarjustFlorezMD
Leave it to @BalazsHalmosMD to stay 1. current 2. informative and absolutely 3. hilarious ๐ Amazing conversations happening here at #BTGLung2025 discussing the perioperative early stage NSCLC treatment landscape! #ColdplayConcert @NarjustFlorezMD @DrEdKim
0
3
28
Fantastic work together with @Alfdoc2 @jillfeldman4 and my global colleagues. Now we have identified clinical and molecular poor prognostic factors, we just have to push forward to improve outcomes for those patients. @MDAndersonNews @lungoncdoc @OncoViews @oncodaily
Hot off the press a ๐จ Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. ๐ https://t.co/lXqpF2fSot thanks to all the co-authors, great team
0
8
29